Versant Venture Capital VI Amends Monte Rosa Therapeutics Stake

TL;DR

Versant Venture Capital VI updated its 13D filing for Monte Rosa Therapeutics. Watch for more details.

AI Summary

Versant Venture Capital VI, L.P. filed an amendment (No. 3) to its Schedule 13D on September 24, 2024, regarding its holdings in Monte Rosa Therapeutics, Inc. The filing indicates a change in beneficial ownership, though specific share counts or dollar values are not detailed in this excerpt. The filing is an update to previous disclosures concerning Versant's investment in the company.

Why It Matters

This amendment signals a potential shift in the ownership structure or strategy of Monte Rosa Therapeutics, which could impact its stock price and future corporate actions.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position, which can lead to increased stock volatility.

Key Players & Entities

• Versant Venture Capital VI, L.P. (company) — Filing entity
• Monte Rosa Therapeutics, Inc. (company) — Subject company
• VERSANT VANTAGE I GP, L.P. (company) — Group member
• VERSANT VANTAGE I GP-GP, LLC (company) — Group member
• VERSANT VANTAGE I, L.P. (company) — Group member
• VERSANT VENTURES VI GP, L.P. (company) — Group member
• VERSANT VENTURES VI GP-GP, LLC (company) — Group member

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $6.0000 — t a weighted average price per share of $6.0000 for aggregate proceeds of approximately
• $3,251,382.00 — for aggregate proceeds of approximately $3,251,382.00. On September 12, 2024, Versant VI so
• $6.0017 — t a weighted average price per share of $6.0017 for aggregate proceeds of approximately
• $96,309.28 — for aggregate proceeds of approximately $96,309.28. On September 13, 2024, Versant VI so
• $6.1603 — t a weighted average price per share of $6.1603 for aggregate proceeds of approximately
• $57,100.17 — for aggregate proceeds of approximately $57,100.17. On September 20, 2024, Versant VI so
• $6.5296 — t a weighted average price per share of $6.5296 for aggregate proceeds of approximately
• $7,395,208.17 — for aggregate proceeds of approximately $7,395,208.17. SIGNATURE After reasonable inquiry

Filing Documents

• d883694dsc13da.htm (SC 13D/A) — 108KB
• 0001193125-24-224875.txt ( ) — 110KB

From the Filing

SC 13D/A 1 d883694dsc13da.htm SC 13D/A SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERE TO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Monte Rosa Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 61225M102 (CUSIP Number) Versant Venture Capital VI, L.P. Max Eisenberg One Sansome Street, Suite 1650 San Francisco, CA 94104 415-801-8100 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) September 20, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 61225M102 13D 1. Name of Reporting Persons Versant Venture Capital VI, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Source of Funds (See Instructions) WC 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 5,099,336 shares of common stock (1) 8. Shared Voting Power 0 9. Sole Dispositive Power 5,099,336 shares of common stock (1) 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5,099,336 shares of common stock (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row 11 8.3% (2) 14. Type of Reporting Person (See Instructions) PN (1) These shares are held by Versant VI (as defined in Item 2(a) of the Original Schedule 13D). Versant Ventures VI GP-GP (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Versant Ventures VI GP (as defined in Item 2(a) of the Original Schedule 13D), which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI. (2) Based upon 61,372,824 shares of the Issuers Common Stock (as defined in Item 1 of the Original Schedule 13D) outstanding as of August 5, 2024, as set forth in the Issuers quarterly report on Form 10-Q for the quarter ended June 30, 2024, filed with the United States Securities and Exchange Commission (the Commission) on August 8, 2024 (the Form 10-Q) CUSIP No. 61225M102 13D 1. Name of Reporting Persons Versant Ventures VI GP, L.P. 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC Use Only 4. Source of Funds (See Instructions) AF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e) 6. Citizenship or Place of Organization Delaware Number of Shares Beneficially Owned by Each Reporting Person With 7. Sole Voting Power 0 8. Shared Voting Power 5,099,336 shares of common stock (1) 9. Sole Dispositive Power 0 10. Shared Dispositive Power 5,099,336 shares of common stock (1) 11. Aggregate Amount Beneficially Owned by Each Reporting Person 5,099,336 shares of common stock (1) 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row 11 8.3% (2) 14. Type of Reporting Person (See Instructions) PN (1) These shares are held by Versant VI. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP, which is the general partner of Versant VI. Each of Versant Ventures VI GP-GP and Versant Ventures VI GP may be deemed to share voting, investment and dispositive power with respect to the shares held by Versant VI. (2) Based upon 61,372,824 shares of the Issuers Common Stock outstanding as of August 5, 2024, as set forth in the Form 10-Q. CUSIP No. 61225M102 13D 1. Name of Reporting Persons Versant Ventures VI GP-GP, LLC 2. Check the Appropriate Box if a Member of a Group (See

View Full Filing

View this SC 13D/A filing on SEC EDGAR